CYCLERION THERAPEUTICS INC (CYCN)

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

Cyclerion Therapeutics just reported results for the fourth quarter of 2023.

CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclerion Therapeutics (NASDAQ:CYCN) just reported results for the fourth quart...

Cyclerion Appoints Regina Graul, Ph.D., as President

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep...

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

        – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in...

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it...

Cyclerion announces 1 for 20 reverse stock split (NASDAQ:CYCN)

Cyclerion Therapeutics (CYCN) announced a reverse stock split of its outstanding common shares at a ratio of 1-for-20, effective as of 5:00 p.m

Cyclerion Announces Reverse Stock Split

Cyclerion Announces Reverse Stock Split

CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN)...

Cyclerion Therapeutics down 6% on spin off agreement (NASDAQ:CYCN)

Cyclerion Therapeutics (CYCN) enter agreement to sell two of its sGC stimulator assets in exchange for cash and equity ownership to a new private company

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction ...

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash...

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the...

Cyclerion's zagociguat gets FDA orphan drug status (NASDAQ:CYCN)

Cyclerion Therapeutics (CYCN) shares gained 8% premarket on Monday after the clinical-stage biopharmaceutical company received U.S

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission...

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday!